Bionomics Share Price and Company Fundamentals
Last traded: Today at 3:36 AM
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.
|Primary activities||Developer of innovative treatments for cancer and diseases of the central nervous system.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||31 Dalgleish Street Thebarton SA 5031 Australia|
|Phone / Fax||61 8 8354 6100 / 61 8 8354 6199|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Bionomics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Bionomics.
|Dr. Errol B. De Souza||Exec. Chairman||67||363.28k|
|Mr. Adrian Hinton||Acting Chief Financial Officer||265.5k|
|Prof. Paul Rolan||Consultant Chief Medical Officer of Clinical Neuroscience|
|Ms. Suzanne Irwin B.Com., FCIS||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Bionomics is 220.67M and its enterprise value is 173.07M. The enterprise value to revenue ratio of BNO is 78.88.
The BNO's stocks Beta value is 2.86 making it 186% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Bionomics (BNO)
Bionomics (ASX:BNO) Frequently Asked Questions
1. What is Bionomics's Stock Symbol?
Bionomics trades on ASX under the ticker symbol "BNO".
2. What is Bionomics's stock price today?
One share of BNO stock can currently be purchased for approximately $0.21.
3. How can I contact Bionomics?
Bionomics's mailing address is 31 Dalgleish Street Thebarton SA 5031 Australia. The company can be reached via phone at 61 8 8354 6100.
4. What is Bionomics's official website?
The official website of Bionomics is http://www.bionomics.com.au.
5. Which share registry manages Bionomics's stock?
Bionomics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.